TAIWAN · TWSE / TPEx
Alar
昱展新藥 · 6785 · TPEx (OTC) · Biotech and medical
Share price, 2026-10-19NT$86.401 month -8.1% · 1 year -69.3%
Directors and supervisors hold8,470,00012.7% of shares issued
Of which pledged0.0%0
Major shareholders (10%+) hold13,864,41220.8% of shares issued
Revenue, 2026-09—year on year
Share price, last 12 months
Daily closes adjusted for cash and stock dividends, against the TAIEX index rebased to the same start. Prices from Yahoo Finance.
Directors, officers and major shareholders
Holdings reported for 2026-09. At election = shares held when the director was elected. Related parties = holdings of the person's spouse, minor children and nominees. One person with two roles is listed once.
| Person | Role | At election | Now | Of the company | Pledged | Related parties |
|---|---|---|---|---|---|---|
| 林東和 | Chairman · Major shareholder (10%+) | 7,050,000 | 7,050,000 | 10.55% | — | 8,612,513 |
| 文永順 | Director · President | 220,000 | 220,000 | 0.33% | — | 3,400,000 |
| 薩摩亞商GRAND SPIRIT INVESTM | Director | 1,200,000 | 1,200,000 | 1.80% | — | — |
| 梁芮瑋 | Director (corporate representative) | — | 32,000 | 0.05% | — | — |
| 方承猷 | Director | — | 0 | — | — | 728,284 |
| 李水盛 | Independent director | — | 0 | — | — | — |
| 梁淑琴 | Independent director | — | 0 | — | — | — |
| 蘇美琍 | Independent director | — | 0 | — | — | — |
| 劉淑華 | Major shareholder (10%+) | — | 6,814,412 | 10.20% | — | 7,648,101 |
| 康宇寧 | Chief financial officer · Chief accountant | — | 30,000 | 0.04% | — | — |
Exchange announcements
| Date | |
|---|---|
| 2026-10-16 | 本公司已向美國FDA提交新劑型新藥ALA-3000用於 難治型憂鬱症之臨床二期試驗申請 |